CN117562948A - 一种辅助治疗前列腺肥大的中药组合物及其制备方法 - Google Patents
一种辅助治疗前列腺肥大的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN117562948A CN117562948A CN202311657382.0A CN202311657382A CN117562948A CN 117562948 A CN117562948 A CN 117562948A CN 202311657382 A CN202311657382 A CN 202311657382A CN 117562948 A CN117562948 A CN 117562948A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- prostatic hyperplasia
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 41
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000009098 adjuvant therapy Methods 0.000 title claims description 14
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 241000759271 Alangium Species 0.000 claims abstract description 22
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 22
- 241001164374 Calyx Species 0.000 claims abstract description 11
- 244000064622 Physalis edulis Species 0.000 claims abstract description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 10
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 10
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 9
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 9
- 235000002912 Salvia officinalis Nutrition 0.000 claims abstract description 9
- 235000002020 sage Nutrition 0.000 claims abstract description 9
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 6
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 6
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 4
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 4
- 241001529742 Rosmarinus Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 230000002829 reductive effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000001179 sorption measurement Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 240000007232 Illicium verum Species 0.000 claims description 9
- 235000008227 Illicium verum Nutrition 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000004062 sedimentation Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000722953 Akebia Species 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 241000157352 Uncaria Species 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 244000182022 Salvia sclarea Species 0.000 claims 1
- 235000002911 Salvia sclarea Nutrition 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 18
- 230000027939 micturition Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 7
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract description 3
- 241000203383 Schefflera Species 0.000 abstract description 3
- 206010046555 Urinary retention Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 14
- 210000000582 semen Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 6
- 229960004039 finasteride Drugs 0.000 description 6
- 239000013641 positive control Substances 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 208000017497 prostate disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 244000270834 Myristica fragrans Species 0.000 description 2
- 235000009421 Myristica fragrans Nutrition 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000046198 Triteleia hyacinthina Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 239000001702 nutmeg Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 241000161260 Alangium chinense subsp. pauciflorum Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 244000262613 Michelia alba Species 0.000 description 1
- 235000003415 Michelia alba Nutrition 0.000 description 1
- 244000174681 Michelia champaca Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001465382 Physalis alkekengi Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000203379 Schefflera arboricola Species 0.000 description 1
- 241000133425 Stauntonia Species 0.000 description 1
- 240000001490 Stauntonia hexaphylla Species 0.000 description 1
- 235000014570 Stauntonia hexaphylla Nutrition 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZHKVKULEJZXSLW-KZZGZOJNSA-N beta-daucosterol Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(O)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ZHKVKULEJZXSLW-KZZGZOJNSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- PJWPOUFMMWFJOL-UHFFFAOYSA-N beta-sitosterol-beta-D-glucoside Natural products CCC(CCC(C)C1CCC2C3C=CC4CC(CCC4(C)C3CCC12C)OC5OC(CO)C(O)C(O)C5O)C(C)C PJWPOUFMMWFJOL-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical group O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种辅助治疗前列腺肥大的中药组合物及其制备方法,该中药组合物是由钩藤、稀花八角枫乙醇提取物、木通七叶莲、莲房、锦灯笼、迷迭香、甜杏仁、肉桂、快乐鼠尾草经加工制备而成;该中药组合物具有治疗前列腺肥大的作用;主要用于前列腺肥大,症状包括尿频、尿急和尿不尽;本发明的中药组合物能够降低前列腺肥大患者的前列腺指数,调节性激素水平,降低前列腺性磷酸酶活力,对治疗前列腺肥大引起的尿频、尿急和尿不尽问题效果显著,同时该组合物是以中药为原材料,使用安全,生物利用度高,且无任何毒副作用。
Description
技术领域
本发明涉及中药制备技术领域,特别涉及一种辅助治疗前列腺肥大的中药组合物及其制备方法。
背景技术
前列腺肥大又称前列腺增生,是老年男子常见疾病之一。症状主要表现为两组症状,一类是膀胱刺激症状;另一类是因增生前列腺阻塞尿路产生的梗阻性症状。膀胱刺激症状:尿频、尿急、夜尿增多及急迫性尿失禁。尿频是前列腺增生的早期信号,尤其夜尿次数增多更有临床意义。该病有三个主要特征:前列腺体积增大;膀胱出口阻塞;有排尿困难、尿频、尿急等下尿路症状。
正常男性到了老年阶段,身体各个器官、组织都在萎缩,唯独前列腺是增生的,病变长期可引起肾积水和肾功能损害,还可并发结石、感染、肿瘤等。前列腺增生的发病机理,到目前为止还没有办法明确,发病原因尚不清楚并开始呈低龄化趋势。前列腺是人体唯一没有血管的腺体,打针吃药输液对前列腺都无效!目前临床上,确诊为无症状或轻微症状转移去势抵抗性前列腺癌(mCRPC)的患者,在临床上尚无治愈的选择,目前治疗手段以口服激素类小分子药和化疗为主。以往的中药、西药及手术治疗是有严重缺陷的。表现在几个方面:一、西药副作用大:肝肾受到损坏,加重基础疾病的发展,前列腺增生越治疗越严重;二、手术治疗治标不治本,复发率比较高,成本也高,还非常痛苦,一旦复发不易再次手术;三、口服中药、贴剂、理疗、外用栓剂等,药物配方不科学,达不到效果。因此,急需找到一种无副作用和使用方便的治疗方法。
发明内容
针对现有技术的上述缺陷,本发明提出一种辅助治疗前列腺肥大的中药组合物及其制备方法,以解决上述背景技术提出的问题。
为达到上述目的,本发明提供如下技术方案:
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:15~20份钩藤(Uncariarhynchophylla(Miq.)Miq.ex Havil.)、10~20份稀花八角枫(Alangiumchinense subsp.pauciflorum的根及根茎)乙醇提取物、5~15份木通七叶莲(为木通科野木瓜属植物鸭脚莲(尾叶野木瓜)Stauntonia hexaphylla(Thunb.)Decne.var.urophyllaHand.-Mazz.和野木瓜S.chinensis DC.,以根或全株入药)、8~18份莲房(睡莲科植物莲Nelumbo nucifera的干燥花托)、2~9份锦灯笼(茄科植物酸浆Physalis alkekengiL.var.Franchetii(Mast.)Makino的干燥宿萼或带果实的宿萼)、3~12份迷迭香、3~10份甜杏仁、2~6份肉桂、2~7份快乐鼠尾草。
优选地,一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:18份钩藤、15份稀花八角枫乙醇提取物、10份木通七叶莲、12份莲房、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
优选地,所述稀花八角枫乙醇提取物的制备方法步骤如下:
(1)以干燥的稀花八角枫根及根茎为原料,破碎后投入提取罐中;加入85~95%乙醇,采取减压加热回流提取,在真空度-0.08~-0.1MPa,温度50~80℃下进行提取,乙醇体积用量是原料的4~6倍,提取2~4次,每次提取时间为30~50min,得提取液;
(2)合并步骤(1)所得的提取液,再进行减压浓缩,浓缩条件:真空度范围-0.08~-0.1MPa,温度60~75℃,浓缩1~3h,得浓缩液;
(3)将步骤(2)所得的浓缩液离心,在转速4000~5000r/min,离心时间100~150min条件下沉降分离,取上清液;
(4)沉降分离后的上清液通过HPD-100大孔吸附树脂柱,用纯化水洗至流出液呈中性,然后用60~75%乙醇溶液进行洗脱,收集该梯度乙醇洗脱液2~4倍柱体积;其中HPD-100大孔吸附树脂与原料质量比为1:15~20;
(5)将步骤(4)所得的乙醇洗脱液在60~75℃条件下,-0.06~-0.08MPa条件下减压浓缩至相对密度为1.10~1.50后,将浓缩液放置5~10h,用0.45μm滤纸抽滤,最后经过真空干燥2~3h,可得稀花八角枫乙醇提取物。
优选地,稀花八角枫乙醇提取物主要成分是β-胡萝卜苷。
优选地,一种辅助治疗前列腺肥大的中药组合物的制备方法,将所述重量份的原料进行粉碎至80目,用水提取2~4次,每次加入原料15~20倍重量的水,煎煮1~3h,200目筛网过滤并合并滤液,将滤液浓缩至相对密度为1.00~1.25的浸膏,干燥1.5h后粉碎得到中药组合物。
优选地,所述中药组合物在制备治疗前列腺肥大疾病药物中的应用。
现有技术:采用中国专利CN109793866A公开名称为“一种治疗男性前列腺疾病的中药及制备方法”的专利申请制备中药,中药组成配方为:金银花18-22、鱼腥草13-17、茯苓9-11、桃仁9-11、黄精4-6、益智仁4-6、罗汉果4-6、丁香4-6、肉桂4-6、白扁豆2-4、决明子2-4、肉豆蔻2-4、沙棘2-4、牡蛎0.5-1.5、鸡内金0.5-1.5、昆布0.5-1.5。申请人对以上现有技术进行研究试验,发现此发明中药对治疗前列腺疾病的效果不理想。因此研发一种辅助治疗前列腺肥大的中药组合物,能为治疗前列腺肥大问题带来一种新的治疗手段。
与现有技术相比,本发明的有益效果是:
(1)本发明的中药组合物能够降低前列腺肥大患者的前列腺指数,调节性激素水平,降低前列腺性磷酸酶活力,对治疗前列腺肥大引起的尿频、尿急和尿不尽问题效果显著,同时该组合物是以中药为原材料,使用安全,生物利用度高,且无任何毒副作用。
(2)钩藤和稀花八角枫是苗族传统药里的一味经典药,稀花八角枫具有毒藜碱成分,该类成分对人体具有毒性,导致稀花八角枫的使用范围受限,本申请通过配方的合理配伍,充分发挥中药中含有的活性成分主要包括多酚类、黄酮类和多糖类等等,为钩藤和稀花八角枫提供一种新的用途。
具体实施方式
下面结合具体实施方式对本发明的技术方案作进一步详细地说明。
实施例1
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:15份钩藤、10份稀花八角枫乙醇提取物、5份木通七叶莲、8份莲房、2份锦灯笼、3份迷迭香、3份甜杏仁、2份肉桂、2份快乐鼠尾草。
稀花八角枫乙醇提取物的制备方法步骤如下:
(1)以干燥的稀花八角枫根及根茎为原料,破碎后投入提取罐中;加入85%乙醇,采取减压加热回流提取,在真空度-0.08MPa,温度50℃下进行提取,乙醇体积用量是原料的4~6倍,提取2次,每次提取时间为30min,得提取液;
(2)合并步骤(1)所得的提取液,再进行减压浓缩,浓缩条件:真空度范围-0.08MPa,温度60℃,浓缩1h,得浓缩液;
(3)将步骤(2)所得的浓缩液离心,在转速4000r/min,离心时间100min条件下沉降分离,取上清液;
(4)沉降分离后的上清液通过HPD-100大孔吸附树脂柱,用纯化水洗至流出液呈中性,然后用60%乙醇溶液进行洗脱,收集该梯度乙醇洗脱液2倍柱体积;其中HPD-100大孔吸附树脂与原料质量比为1:15;
(5)将步骤(4)所得的乙醇洗脱液在60℃条件下,-0.06MPa条件下减压浓缩至相对密度为1.10后,将浓缩液放置5h,用0.45μm滤纸抽滤,最后经过真空干燥2h,可得稀花八角枫乙醇提取物。
一种辅助治疗前列腺肥大的中药组合物的制备方法,将所述重量份的原料进行粉碎至80目,用水提取2次,每次加入原料15倍重量的水,煎煮1h,200目筛网过滤并合并滤液,将滤液浓缩至相对密度为1.00的浸膏,干燥1.5h后粉碎得到中药组合物。
实施例2
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:20份钩藤、20份稀花八角枫乙醇提取物、15份木通七叶莲、18份莲房、9份锦灯笼、12份迷迭香、10份甜杏仁、6份肉桂、7份快乐鼠尾草。
稀花八角枫乙醇提取物的制备方法步骤如下:
(1)以干燥的稀花八角枫根及根茎为原料,破碎后投入提取罐中;加入95%乙醇,采取减压加热回流提取,在真空度-0.1MPa,温度80℃下进行提取,乙醇体积用量是原料的6倍,提取4次,每次提取时间为50min,得提取液;
(2)合并步骤(1)所得的提取液,再进行减压浓缩,浓缩条件:真空度范围-0.1MPa,温度75℃,浓缩3h,得浓缩液;
(3)将步骤(2)所得的浓缩液离心,在转速5000r/min,离心时间150min条件下沉降分离,取上清液;
(4)沉降分离后的上清液通过HPD-100大孔吸附树脂柱,用纯化水洗至流出液呈中性,然后用75%乙醇溶液进行洗脱,收集该梯度乙醇洗脱液4倍柱体积;其中HPD-100大孔吸附树脂与原料质量比为1:20;
(5)将步骤(4)所得的乙醇洗脱液在75℃条件下,-0.08MPa条件下减压浓缩至相对密度为1.50后,将浓缩液放置10h,用0.45μm滤纸抽滤,最后经过真空干燥3h,可得稀花八角枫乙醇提取物。
一种辅助治疗前列腺肥大的中药组合物的制备方法,将所述重量份的原料进行粉碎至80目,用水提取4次,每次加入原料20倍重量的水,煎煮3h,200目筛网过滤并合并滤液,将滤液浓缩至相对密度为1.25的浸膏,干燥1.5h后粉碎得到中药组合物。
实施例3
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:18份钩藤、15份稀花八角枫乙醇提取物、10份木通七叶莲、12份莲房、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
稀花八角枫乙醇提取物的制备方法步骤如下:
(1)以干燥的稀花八角枫根及根茎为原料,破碎后投入提取罐中;加入90%乙醇,采取减压加热回流提取,在真空度-0.09MPa,温度60℃下进行提取,乙醇体积用量是原料的5倍,提取3次,每次提取时间为40min,得提取液;
(2)合并步骤(1)所得的提取液,再进行减压浓缩,浓缩条件:真空度范围-0.09MPa,温度70℃,浓缩2h,得浓缩液;
(3)将步骤(2)所得的浓缩液离心,在转速4500r/min,离心时间120min条件下沉降分离,取上清液;
(4)沉降分离后的上清液通过HPD-100大孔吸附树脂柱,用纯化水洗至流出液呈中性,然后用70%乙醇溶液进行洗脱,收集该梯度乙醇洗脱液3倍柱体积;其中HPD-100大孔吸附树脂与原料质量比为1:18;
(5)将步骤(4)所得的乙醇洗脱液在70℃条件下,-0.07MPa条件下减压浓缩至相对密度为1.25后,将浓缩液放置8h,用0.45μm滤纸抽滤,最后经过真空干燥2~2.5,可得稀花八角枫乙醇提取物。
一种辅助治疗前列腺肥大的中药组合物的制备方法,将所述重量份的原料进行粉碎至80目,用水提取3次,每次加入原料18倍重量的水,煎煮2h,200目筛网过滤并合并滤液,将滤液浓缩至相对密度为1.15的浸膏,干燥1.5h后粉碎得到中药组合物。
对比例1
本对比例与实施例3区别在于:中药组合物中不添加钩藤,其余成分和步骤不变。
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:15份稀花八角枫乙醇提取物、10份木通七叶莲、12份莲房、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
对比例2
本对比例与实施例3区别在于:中药组合物中不添加木通七叶莲,其余成分和步骤不变。
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:18份钩藤、15份稀花八角枫乙醇提取物、12份莲房、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
对比例3
本对比例与实施例3区别在于:中药组合物中不添加莲房,其余成分和步骤不变。
一种辅助治疗前列腺肥大的中药组合物,包括以下重量份的原料:18份钩藤、15份稀花八角枫乙醇提取物、10份木通七叶莲、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
对比例4
采用中国专利CN109793866A公开名称为“一种治疗男性前列腺疾病的中药及制备方法法”的专利申请制备中药,中药组成配方为:金银花18-22、鱼腥草13-17、茯苓9-11、桃仁9-11、黄精4-6、益智仁4-6、罗汉果4-6、丁香4-6、肉桂4-6、白扁豆2-4、决明子2-4、肉豆蔻2-4、沙棘2-4、牡蛎0.5-1.5、鸡内金0.5-1.5、昆布0.5-1.5。
试验例1对前列腺增生模型的影响
1.材料
动物:SPF级SD雄性大鼠105只,体重180~200g,购自北京维通利华实验动物技术有限公司。饲养过程中保持室温24℃,12h光照昼夜循环,空气流通,自由饮食饮水,适应性喂养7d。
药物:本发明实施例1~3和对比例1~4制备所得的中药组合物;水合氯醛,天津市天力化学试剂有限公司;丙酸睾丸酮注射液,1ml:25mg,批准文号:兽药字110251054,购自宁波第二激素厂;苯甲酸雌二醇(E2)注射液,购自宁波第二激素厂;非那雄胺片,5mg/片,批准文号:国药准字J20150143,购自杭州默沙东制药有限公司;硫酸庆大霉素注射液,购自天津金耀药业有限公司;4%多聚甲醛,购自北京索莱宝生物科技有限公司。雌/雄激素(E2/T)1:100混合液:混合液中E2浓度100μg/mL,即每100mL混合液中含10mL苯甲酸雌二醇注射液(E2,1mg/mL)和40mL丙酸睾酮注射液(T,25mg/mL),以及50mL橄榄油,混匀后室温保存,一周一配。
2.试验方法
2.1造模与分组
大鼠适应性喂养1周后,按0.3mL/100g腹腔注射10%水合氯醛麻醉,随机选取95只大鼠,小鼠阴囊皮肤消毒后,摘除双侧睾丸,缝合。剩余10只大鼠进行假手术(按照手术流程操作,暴露睾丸,除不摘除睾丸外,其余操作与大鼠去势造模相同),缝合。然后注射青霉素20万U/kg/d,连续7d。
造模后第8d,从摘除双侧睾丸的大鼠中挑选90只恢复较好的模型大鼠,随机分为9组,分别作为模型对照组、非那雄胺阳性对照组、实施例1~3组和对比例1~4组,每组10只;以假手术组作为空白对照组。除空白对照组外,其余各组按照0.5ml/kg的剂量,皮下注射雌/雄激素(E2/T)1∶100混合液,每天1次,连续30d,空白对照组注射等量溶媒橄榄油。
2.2给药方法
从第8d开始,实施例1~3组和对比例1组分别给予本发明实施例1~3和对比例1所制备的药物1.35g/kg/d(相当于人临床给药剂量的0.5倍);非那雄胺阳性对照组用药量0.83mg/kg/d(相当于临床用药量的10倍),模型对照组给无菌水。以上均采用灌胃给药,连续30d(给药期间每周称体重1次以调整剂量)。
2.3标本的采集
末次给药后,禁食12h,称重大鼠体质量。眼眶取血,离心,取血清,置-20℃冰箱保存。脱颈椎处死大鼠,立即打开腹腔,剥离前列腺周围组织,摘取前列腺,迅速称量前列腺质量,组织保存于-80℃冰箱。
2.4指标测定
2.4.1前列腺指数的测定
计算公式为:前列腺指数=前列腺湿质量/体质量(mg/g)
2.4.2性激素水平的测定
取大鼠血清,采用ELISA法,按照说明书采用酶联免疫法,在450nm波长下测定血清中睾酮(T)、双氢睾酮(DHT)、雌二醇注射液(E2)的浓度。
2.4.3大鼠前列腺性磷酸酶(PACP)的检测
根据PACP试剂盒操作,检测血清中PACP活力。
3.试验结果
结果如表1、表2和表3所示:
表1前列腺指数的测定
从表1可知,与空白对照组相比,模型对照组大鼠的前列腺湿重及前列腺指数均有增加,说明前列腺增生模型造模成功。与模型对照组相比,非那雄胺阳性对照组、实施例1~3组和对比例1~4组可以降低前列腺指数,且实施例3组的效果最好。试验结果表明,本发明药物能够治疗前列腺增生,且实施例3组配方的配比最佳。
表2性激素水平的测定
从表2可知,与空白对照组相比,模型对照组大鼠前列腺T水平显著降低,前列腺DHT和E2水平升高,表明大鼠前列腺增生模型建立成功。与模型对照组相比,非那雄胺阳性对照组和对比例1~4组的大鼠前列腺T水平升高,前列腺DHT和E2水平降低。本发明的实施例1~3所制备的中药组合物可以升高大鼠前列腺T水平,并可以降低前列腺DHT和E2水平,表明该中药组合物对前列腺增生有抑制作用。
表3对大鼠血清中PACP活力的影响
从表3可知,与空白对照组相比,模型对照组大鼠血清中PACP活力升高。与模型对照组相比,本发明实施例1~3组、非那雄胺阳性对照组和对比例1~4组均可降低模型大鼠血清中的PACP活力,说明本发明药物对前列腺组织生长有一定的抑制作用。
试验例2对大鼠尿量的影响
2.1试验材料
动物:SPF级SD雄性大鼠40只,体重180~200g。药物:实施例1~3所制得的中药组合物。
2.2试验方法
SD雄性大鼠随机分成4组,每组10只。实验前大鼠禁食不禁水16h,各组按20ml/kg体重剂量腹腔注射生理盐水,并轻压下腹部使膀胱排空,接着灌胃给药,实施例1~3组灌胃给药量为1.0/kg;对照组灌胃同体积的生理盐水。给药后立即将大鼠放入代谢笼内,按大鼠代谢笼实验法收集药后6h内总尿液量。
2.3试验结果
结果如表4所示:
表4对大鼠排尿量的影响
从表4可知,与对照组相比,实施例1~3组对大鼠给药后6h内尿量增加,对大鼠有利尿作用。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种辅助治疗前列腺肥大的中药组合物,其特征在于,包括以下重量份的原料:15~20份钩藤、10~20份稀花八角枫乙醇提取物、5~15份木通七叶莲、8~18份莲房、2~9份锦灯笼、3~12份迷迭香、3~10份甜杏仁、2~6份肉桂、2~7份快乐鼠尾草。
2.根据权利要求1所述的辅助治疗前列腺肥大的中药组合物,其特征在于,包括以下重量份的原料:18份钩藤、15份稀花八角枫乙醇提取物、10份木通七叶莲、12份莲房、7份锦灯笼、10份迷迭香、5份甜杏仁、4份肉桂、5份快乐鼠尾草。
3.根据权利要求1所述的辅助治疗前列腺肥大的中药组合物,其特征在于,所述稀花八角枫乙醇提取物的制备方法步骤如下:
(1)以干燥的稀花八角枫根及根茎为原料,破碎后投入提取罐中;加入85~95%乙醇,采取减压加热回流提取,在真空度-0.08~-0.1MPa,温度50~80℃下进行提取,乙醇体积用量是原料的4~6倍,提取2~4次,每次提取时间为30~50min,得提取液;
(2)合并步骤(1)所得的提取液,再进行减压浓缩,浓缩条件:真空度范围-0.08~-0.1MPa,温度60~75℃,浓缩1~3h,得浓缩液;
(3)将步骤(2)所得的浓缩液离心,在转速4000~5000r/min,离心时间100~150min条件下沉降分离,取上清液;
(4)沉降分离后的上清液通过HPD-100大孔吸附树脂柱,用纯化水洗至流出液呈中性,然后用60~75%乙醇溶液进行洗脱,收集该梯度乙醇洗脱液2~4倍柱体积;其中HPD-100大孔吸附树脂与原料质量比为1:15~20;
(5)将步骤(4)所得的乙醇洗脱液在60~75℃条件下,-0.06~-0.08MPa条件下减压浓缩至相对密度为1.10~1.50后,将浓缩液放置5~10h,抽滤,最后经过真空干燥,可得稀花八角枫乙醇提取物。
4.如权利要求1~3任一项所述的辅助治疗前列腺肥大的中药组合物的制备方法,其特征在于,将所述重量份的原料进行粉碎,用水提取2~4次,每次加入原料15~20倍重量的水,煎煮1~3h,筛网过滤并合并滤液,将滤液浓缩至相对密度为1.00~1.25的浸膏,干燥粉碎后得到中药组合物。
5.如权利要求1所述的辅助治疗前列腺肥大的中药组合物,其特征在于,所述中药组合物在制备治疗前列腺肥大疾病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311657382.0A CN117562948A (zh) | 2023-12-06 | 2023-12-06 | 一种辅助治疗前列腺肥大的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311657382.0A CN117562948A (zh) | 2023-12-06 | 2023-12-06 | 一种辅助治疗前列腺肥大的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117562948A true CN117562948A (zh) | 2024-02-20 |
Family
ID=89886200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311657382.0A Pending CN117562948A (zh) | 2023-12-06 | 2023-12-06 | 一种辅助治疗前列腺肥大的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117562948A (zh) |
-
2023
- 2023-12-06 CN CN202311657382.0A patent/CN117562948A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145064B (zh) | 一种治疗老年性阴道炎的中药组合物及其制备方法 | |
CN103520618A (zh) | 一种秋葵植物伟哥的制备方法 | |
CN115337356A (zh) | 一种治疗类风湿关节炎的药物组合物及其制备方法 | |
CN104208418A (zh) | 一种固精缩尿补肾的金樱子保健口服液及其制备方法 | |
CN114848780B (zh) | 预防子宫内膜异位症术后复发的中药组合物及其制备方法 | |
CN117562948A (zh) | 一种辅助治疗前列腺肥大的中药组合物及其制备方法 | |
CN101590126B (zh) | 一种治疗良性前列腺增生的中药复方 | |
CN103536818B (zh) | 佛籽软胶囊及其制备方法 | |
JPH1192391A (ja) | 月経困難症の予防又は治療に有効な医薬組成物 | |
CN105902951A (zh) | 联合化疗药治疗骨肉瘤的中药复方组合物 | |
CN110917249A (zh) | 一种用于前列腺的中药组合物及其制备方法和应用 | |
CN116270870B (zh) | 一种治疗膜性肾病的中药组合物及其制备方法 | |
CN101371896A (zh) | 一种治疗子宫内膜异位症的药物制剂及其制备方法 | |
CN104491677A (zh) | 一种治疗性功能障碍药物的制备方法 | |
CN103977276A (zh) | 治疗放射性膀胱炎的中药胶囊 | |
CN114404490B (zh) | 用于治疗肿瘤放化疗后白细胞减少症的中药及制备方法 | |
CN103251751B (zh) | 一种治疗原发性痛经的中药组合物及其制备方法 | |
CN115919939B (zh) | 一种治疗乳腺增生的中药组合物及其制备方法与应用 | |
WO2004084924A1 (fr) | Composition pharmaceutique pour le traitement de l'hypertrophie benigne de la prostate et mode de preparation | |
CN114558090B (zh) | 一种用于治疗良性前列腺增生的药物 | |
CN112439010B (zh) | 一种益气补肾固缩的中药组合物及其应用 | |
CN117462642B (zh) | 一种治疗腹泻的中药组合物及其制备方法和用途 | |
CN115252742B (zh) | 一种用于跌打损伤及骨折的中药口服制剂 | |
CN108354957B (zh) | 马兰或马兰提取物在制备治疗非感染性炎症的药物中的应用及药物 | |
CN101422587A (zh) | 治疗妇科疾病的药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |